RTX: Lots Of Tailwinds, But Little Margin For Error

RTX reported Q2 sales up 14% and EPS up 21%, alongside a record $289B backlog. Management raised 2026 guidance to $95–$96B in sales and $7.10–$7.25 in EPS, citing Raytheon’s defense momentum (Raytheon book-to-bill of 2.42) and improving Pratt & Whitney operations. With GTF issues receding and international orders accelerating, the article points to strengthened multiyear rearmament tailwinds.

Analysis

RTX is starting to look less like a headline-driven defense name and more like a clean earnings-revision story: the market has been discounting execution risk in the engine franchise, so any evidence that repairs are translating into margin and cash flow should drive a higher multiple, not just higher revenue. The larger implication is that backlog visibility now has better quality—if production and aftermarket normalize, the same order book should convert into stronger free cash flow over the next 4-6 quarters, which matters more than top-line growth for re-rating.

On the competitive side, the incremental budget dollar is increasingly being allocated to missile defense, sensors, and sustainment rather than legacy platform builds, which favors RTX’s mix versus peers more exposed to single-program concentration. A subtle second-order effect is that improving Pratt reliability should reduce customer compensation and working-capital drag, freeing capital for buybacks; that can mechanically support EPS even if defense end-markets merely stay stable. The stock is likely to outperform on any confirmation that backlog converts into cash faster than consensus expects.

The main risks are not demand but timing: a U.S. budget delay, export-license friction, or any relapse in Pratt execution could push the thesis out by quarters and keep the multiple capped. The contrarian view is that investors may be overpaying for the headline backlog while underestimating how much of the upside is already in guidance; the real watch item is whether 2025-2026 free cash flow revisions rise faster than EPS. If FCF conversion stalls or guidance is trimmed despite the order book, the thesis breaks.

Key Decisions for Investors

• Add RTX on 2-3% pullbacks or post-guidance consolidation; base case is a 10-15% rerating over 3-6 months if cash conversion improves and estimate revisions keep rising.
• Pair trade: long RTX / short LMT over 3-6 months to express relative execution and backlog-quality outperformance; stop if LMT wins a major program win or RTX margin guidance slips.
• Use RTX as a core defense overweight versus XAR only if you want single-name alpha; otherwise avoid chasing the broad ETF because the upside here is idiosyncratic execution, not just sector beta.
• Watch for a falsifier: any 2025-2026 EPS or FCF guide cut, or a renewed Pratt remediation charge; that would turn this into a dead-money backlog story rather than a re-rating story.